Loading
Galera Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by CHANG NANCY T, was filed 02 Jan 2025.
Insider Decl.
135
Thresholds
n/a
Buy Volume
€25M
48 ops. · all time
Sell Volume
€17M
33 ops. · all time
Who traded when
BuySaleMel Sorensen1 sale
Nancy T. Chang1 buy
Since the insiders bought
- -68.0%Entry US$4.72 · Close at T+365 US$1.51
- -82.7%Entry US$9.11 · Close at T+365 US$1.58
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$16.28
Analyst consensus
Income statement
EBITDA-US$6M
Net incomeUS$63.5M0.0% margin
Valuation
PER (trailing)0.1x
P/Book8.4x
Beta2.61
Balance sheet & cash
Market capUS$3.4B
Free Cash Flow-US$6M
Profitability & ownership
ROA-51.8%
% insiders52.6%
% institutions7.7%
Last declaration on 5 August 2026
Declarations135 total
11 sharesCommon StockSEC:0001193125-26-335215:0
40 sharesCommon StockSEC:0001193125-26-335215:1
2,989,399 sharesCommon StockSEC:0001193125-26-335178:0
975 sharesCommon StockSEC:0001193125-26-335499:0
661,309 sharesCommon StockSEC:0001193125-26-335224:0
47,434 sharesCommon StockSEC:0001193125-26-335224:1
41,631 sharesCommon StockSEC:0001193125-26-335178:1
20,813,818 sharesCommon StockSEC:0001123292-26-000772:0
1,180,611 sharesCommon StockSEC:0000905148-26-001622:0
5,336,870 sharesCommon StockSEC:0000905148-26-001623:0
70,000 shares@ US$0.02010.7% of flowCommon StockSEC:0000905148-25-004171:0
7,644,932 shares@ US$0.0654100.0% of flowCommon StockSEC:0000905148-25-000010:0
Canonical exit: 30 Mar 2025 (T+90)
67,015 shares@ US$0.0722.7% of flowCommon StockSEC:0000950170-24-099168:0
74,202 shares@ US$0.202.1% of flowCommon StockSEC:0001213900-24-038573:16
Canonical exit: 17 Jul 2024 (T+90)
4,342 shares@ US$0.19990.1% of flowCommon StockSEC:0001213900-24-038573:15
Canonical exit: 17 Jul 2024 (T+90)
100 shares@ US$0.18550.0% of flowCommon StockSEC:0001213900-24-038573:17
Canonical exit: 18 Jul 2024 (T+90)
314 shares@ US$0.18740.0% of flowCommon StockSEC:0001213900-24-038573:18
Canonical exit: 18 Jul 2024 (T+90)
215 shares@ US$0.18750.0% of flowCommon StockSEC:0001213900-24-038573:19
Canonical exit: 18 Jul 2024 (T+90)
100,000 shares@ US$0.1912.7% of flowCommon StockSEC:0001213900-24-038573:1
Canonical exit: 16 Jul 2024 (T+90)
68,424 shares@ US$0.1961.9% of flowCommon StockSEC:0001213900-24-038573:2
Canonical exit: 16 Jul 2024 (T+90)
241,028 shares@ US$0.206.9% of flowCommon StockSEC:0001213900-24-038573:3
Canonical exit: 16 Jul 2024 (T+90)
56,900 shares@ US$0.211.7% of flowCommon StockSEC:0001213900-24-038573:4
Canonical exit: 16 Jul 2024 (T+90)
50,000 shares@ US$0.2121.5% of flowCommon StockSEC:0001213900-24-038573:5
Canonical exit: 16 Jul 2024 (T+90)
50,000 shares@ US$0.2141.5% of flowCommon StockSEC:0001213900-24-038573:6
Canonical exit: 16 Jul 2024 (T+90)
243,100 shares@ US$0.227.7% of flowCommon StockSEC:0001213900-24-038573:7
Canonical exit: 16 Jul 2024 (T+90)
25 of 135 declarations
About Galera Therapeutics, Inc.
On November 12, 2019, the first day of the record at Galera Therapeutics, Inc., 6 filers bought for EUR 26,278,923: Sofinnova Venture Partners IX, L.P. for EUR 8,155,530, Novo Holdings A/S for EUR 5,437,020 and New Enterprise Associates 14, L.P. for EUR 4,530,843, all 10% owners. 18 filings are marked as clustered.
On the sales side, Novartis Bioventures Ltd, a 10% owner, sold EUR 7,368,498 on June 19, 2020 and has 14 sales among 16 filings; Novo Holdings A/S sold EUR 4,390,768 on February 18, 2021 and EUR 4,228,191 on October 15, 2020. In all, 52 purchases (51 with an amount) come to EUR 28,029,506, with a median of EUR 34,972, and 33 sales to EUR 17,431,730 (median EUR 45,331), purchases making up 61% of trades.
Read moreShow less
Yair Schneid (10% Owner) filed 28 filings, all purchases, and Jon T. Holmlund (Chief Medical Officer) 27, 13 of them sales. The record gathers 135 filings from 18 filers, including 23 option exercises, and 52.6% of the capital is held by insiders. 2020 has 47 filings, against 29 in both 2019 and 2024. Over the last twelve months: 11 filings, 1 of them a sale.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
